Search for: "Cephalon Inc."
Results 1 - 20
of 173
Sort by Relevance
|
Sort by Date
11 Jan 2022, 11:45 am
In 2015, AstraZeneca and Cephalon paid a total of $54 million to resolve claims that they also improperly reduced AMPs by wrongfully accounting for service fees they paid to wholesalers. [read post]
11 Jan 2022, 11:45 am
In 2015, AstraZeneca and Cephalon paid a total of $54 million to resolve claims that they also improperly reduced AMPs by wrongfully accounting for service fees they paid to wholesalers. [read post]
9 Jan 2022, 8:31 pm
Patents In the United States, PatentlyO reported that Apotex Inc. recently issued a petition for writ of certiorari in the case of Apotex Inc. v Cephalon, Inc., asking the Supreme Court to revisit motivation to combine, obvious to try and whether the non-obvious contribution needs to be an improvement over the prior art. [read post]
6 Jan 2022, 4:50 pm
Cephalon, Inc. [read post]
18 Jun 2019, 6:42 am
Aruba Networks, Inc., C.A. [read post]
8 Jan 2019, 6:38 am
Cephalon, Inc. [read post]
3 Jan 2019, 6:00 am
Cephalon, Inc., C.A. [read post]
31 Dec 2018, 1:25 pm
Cephalon, Inc., C.A. [read post]
14 Nov 2018, 11:33 am
The Department of Justice recently announced that Cephalon, Inc., a biopharmaceutical company, will pay $425 million to settle “off-label marketing”… The post $425 Million Settlement In “Off-Label Marketing” Case appeared first on TZ Legal - Fraud Fighters. [read post]
16 Feb 2018, 2:06 pm
Inc. [read post]
30 Nov 2017, 8:59 pm
Counsel representing several Plaintiffs filed for consolidation of the actions of state, county, and municipal governments and other agencies against opiate manufacturers Purdue Pharma, Teva/Cephalon, Janssen, Endo, Actavis, and Mallinckrodt and distributors McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. [read post]
28 Aug 2017, 10:11 pm
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
28 Aug 2017, 10:11 pm
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
11 Apr 2016, 2:32 pm
The FTC’s complaint attacks two such settlements that Endo Pharmaceuticals Inc. and the Japan-based patent holder for one of the relevant patents reached with generic manufacturers Watson Laboratories (and Watson’s current owner, Allergan plc) and Impax Laboratories, to settle Hatch-Waxman litigation involving Endo’s two most important products—the pain relievers Opana ER® and Lidoderm®.[2] The FTC’s complaint, and its simultaneous… [read post]
19 Mar 2016, 10:13 am
Cephalon, Inc. v. [read post]
15 Jan 2016, 5:32 am
Cephalon, Inc., 620 F. [read post]
8 Dec 2015, 2:22 pm
AstraZeneca LP and Cephalon Inc. paid the United States $26.7 million and $4.3 million, respectively, in separate settlements for allegedly underpaying rebates owed under the Medicaid Drug Rebate Program. [read post]
23 Sep 2015, 5:43 am
Cephalon, Inc., 2015 U.S. [read post]
9 Sep 2015, 6:11 am
LB&B Associates Inc. [read post]
19 Jun 2015, 11:04 am
District Court for the Eastern District of Pennsylvania approved a consent order (the “Consent Order”) between the Federal Trade Commission and defendants Cephalon, Inc. and its parent, Teva Pharmaceutical Industries Ltd.,[1] resolved long-running antitrust litigation stemming from four “reverse payment” settlements of Hatch-Waxman patent infringement cases involving the branded drug Provigil®. [read post]
